{"filings":[{"id":555036,"accession_number":"0000896264-26-000036","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-05-20T20:24:08+00:00","items":["5.07"],"status":"ready","headline":"USANA shareholders re-elect all eight directors, ratify KPMG, approve advisory comp at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Each of eight director nominees received over 13.6M votes for; no nominee had material withheld count.","Ratification of KPMG as auditor: 16,286,742 for, 151,736 against, 29,732 abstain.","Advisory vote on executive compensation: 13,811,489 for, 509,777 against, 13,996 abstain.","Approximately 89% of shares (16,468,210) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.02,"calibrated_materiality_score":0.02,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99561,"accession_number":"0000896264-26-000030","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q1 2026 EPS down 16% YoY to $0.41; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $250M flat YoY; net earnings $7.5M (-20%); diluted EPS $0.41 vs $0.49.","Adjusted diluted EPS $0.61 vs $0.73; adjusted EBITDA $28.4M (-5%).","Core Nutritional active customers 404,000 (-12%); Hiya active subscribers 186,000 (-17%).","Rise Wellness net sales $14M (+741%) from Costco nationwide launch.","Reiterates FY2026 outlook: consolidated net sales $925M–$1.0B; adjusted EPS $1.95–$2.29."],"consensus_eps_estimate":null,"consensus_eps_actual":0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":250218000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115641,"accession_number":"0000896264-26-000014","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q4 net loss $1.8M; core customers down 15%; FY2026 guidance flat to 8% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $1.8M vs profit $4.5M YoY; adjusted diluted EPS $0.60 (down 6% from $0.64).","FY2025 net sales $925M (+8% YoY); core nutritional net sales down 8%, active customers down 15% to 387k.","Recorded $7M goodwill impairment and $6.5M cost realignment charge in Q4, boosting effective tax rate to 72.4%.","FY2026 guidance: consolidated net sales $925M-$1.0B (flat to 8% growth); adjusted diluted EPS $1.95-$2.29.","Hiya net sales grew 17% in FY2025; Rise Wellness net sales tripled; non-core now 16% of consolidated sales."],"consensus_eps_estimate":null,"consensus_eps_actual":0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":925257000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115638,"accession_number":"0000896264-26-000012","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K/A","filed_at":"2026-02-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"USANA sets CEO Guest compensation at $850K base, $1.7M RSU; Brown gets $1.5M severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Brown transitions to strategic advisor through Dec 31, 2026; receives $825K salary, eligible for 2025 bonus, benefits.","Post-separation Brown gets $1.5M severance in three $500K annual installments starting Jan 1, 2027, plus 18 months COBRA.","Kevin Guest named CEO with $850K base salary, target bonus of 100% of base, and $1.7M 2026 RSU grant.","Guest eligible for long-term performance award tied to relative TSR vs Russell 2000 and absolute positive TSR; potential payout up to $3.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115640,"accession_number":"0000896264-26-000005","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA prelim FY2025 sales ~$925M (beat guidance); FY2026 guidance $925M-$1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary FY2025 net sales of ~$925M, above prior guidance of ~$920M.","FY2026 net sales guidance of $925M-$1.0B; core USANA nutritional seen at $720-765M (down from ~$777M).","Hiya segment guided $140-155M (up from ~$132M); Rise Wellness $65-80M (up from ~$16M).","FY2026 is a 52-week year (one week less than FY2025), impacting core business comparison.","Rise Wellness margins expected at breakeven in FY2026 due to growth investments; working capital rising at both Hiya and Rise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115639,"accession_number":"0000896264-26-000002","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"USANA CEO Jim Brown steps down; Kevin Guest returns as CEO effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Brown stepped down as CEO and President after 19 years; will remain in advisory role.","Kevin Guest, former CEO (2015-2023) and current Executive Chairman, reassumes CEO role effective Jan 8, 2026.","Guest continues as Chairman; board cites focus on accelerating growth and long-term opportunities.","Guest led USANA through record results and global expansion during his prior CEO tenure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132071,"accession_number":"0000896264-25-000213","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q3 net loss of $6.5M; lowers FY25 EPS guidance to $0.78 from $1.50-$2.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $214M (+7% YoY) but net loss -$6.5M vs +$10.6M prior year; adj. diluted EPS -$0.15.","Direct selling active customers down 14% to 388,000; Hiya subscribers 193,400 (down 3% sequentially).","FY25 guidance cut sharply: diluted EPS $0.78 (prev $1.50-$2.20); adj. diluted EPS $1.73 (prev $2.35-$3.00).","Effective tax rate jumped to 65% from 45%, causing ~$7.6M income tax expense adjustment in Q3.","Company expects $4.7M restructuring charge in Q4 to align costs with sales; cash $145M, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":699057000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132070,"accession_number":"0000896264-25-000210","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA preliminary Q3 net loss $6.5M, sales $214M, tax rate spikes to 471%; full-year EPS guidance cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $214M (up from $200M YoY) but operating earnings fall to $1.2M from $15.6M.","Diluted EPS loss $0.36 ($0.56 profit in Q3 2024); adjusted EPS loss $0.15.","Effective tax rate 471% due to annual rate change from 45% to 65%, adding ~$7.5M in extra tax.","Full-year sales expected at or near lower end of prior range; EPS below previously issued range.","Hiya (DTC) sales softer but still expected to achieve double-digit growth for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":699057000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148644,"accession_number":"0000896264-25-000178","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q2: net sales +11% to $236M, net earnings -7%; FY guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $236M (+11% YoY); net earnings $9.7M (-7% YoY); diluted EPS $0.52 (-4% YoY).","Adjusted diluted EPS $0.74 (+36% YoY); adjusted EBITDA $30.5M (+13% YoY).","Direct selling Active Customers fell 11% YoY to 418k; Hiya subscribers 200.4k.","Repurchased 528k shares for $15M; ended quarter debt-free with $151M cash.","Reiterated FY2025 outlook: net sales $920M-$1.0B, adjusted EPS $2.35-$3.00."],"consensus_eps_estimate":null,"consensus_eps_actual":1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":485387000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148643,"accession_number":"0000896264-25-000175","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"USANA enters $75M revolving credit facility with Bank of America, $200M accordion option","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $75M revolver replaces prior agreement; includes $200M accordion feature subject to conditions.","Interest on Term SOFR loans at Term SOFR plus 1.75%; commitment fee 0.25%.","Financial covenants: minimum consolidated EBITDA of $80M (step-up to $100M after Q3 2026) and funded debt/EBITDA ≤ 2.0x.","No restrictions on cash dividends or share repurchases under the credit agreement.","Obligations secured by pledge of capital stock of subsidiaries via Amended and Restated Security and Pledge Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167501,"accession_number":"0000896264-25-000144","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02","5.07","8.01"],"status":"ready","headline":"USANA shareholders approve 2025 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected, including Kevin G. Guest and Xia Ding.","2025 Equity Incentive Plan approved, reserving 2.5M shares of common stock for awards.","KPMG LLP ratified as independent registered public accounting firm for fiscal 2025.","Advisory say-on-pay vote approved with ~95% of votes cast in favor.","Plan replaces expiring 2015 Equity Incentive Award Plan; no further grants under prior plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167500,"accession_number":"0000896264-25-000119","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q1 net sales up 10% to $250M; EPS down 43% to $0.49; reiterates FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $250M (+10% YoY); net earnings $9.4M (-43%); diluted EPS $0.49 vs $0.86.","Adjusted diluted EPS $0.73 (-15%); adjusted EBITDA $30M (-10%).","Direct selling Active Customers 459,000 (-7%); Hiya Active Monthly Subscribers 224,000.","FY2025 outlook reaffirmed: consolidated net sales $920M-$1.0B, diluted EPS $1.50-$2.20.","Repurchased 399,000 shares for $12M; $49M remaining under authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":249539000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184799,"accession_number":"0000896264-25-000082","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K/A","filed_at":"2025-03-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"USANA acquires controlling interest in Hiya Health Products; Hiya posts $80.9M revenue, $14.9M net income in 9M 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["USANA acquired controlling interest in Hiya on Dec 23, 2024; audited financials of Hiya now filed.","Hiya's revenue $80.9M, net income $14.9M for nine months ended Sep 30, 2024.","Hiya's FY2023 revenue $68.4M, net loss $467.8K; shows significant growth.","Hiya had $3.85M cash, $8.15M inventory, and zero line-of-credit borrowings as of Sep 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184800,"accession_number":"0000896264-25-000054","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q4 net sales -3% to $214M; net earnings -73% to $4.5M; FY2025 guidance includes Hiya","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $214M (-3% YoY); net earnings $4.5M (-73%); diluted EPS $0.23 (-74%).","FY2024 net sales $855M (-7% YoY); net earnings $42M (-34%); diluted EPS $2.19.","Active customers 454K (-6% YoY); Americas & Europe net sales +1% YoY, Asia Pacific -6%.","Closed acquisition of 78.8% of Hiya on Dec 23, 2024; contributed ~$2M in Q4 sales.","FY2025 outlook: net sales $920M–$1.0B; diluted EPS $1.50–$2.20; adjusted diluted EPS $2.35–$3.00."],"consensus_eps_estimate":null,"consensus_eps_actual":2.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":854503000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201387,"accession_number":"0000896264-24-000235","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"USANA acquires 78.8% stake in Hiya Health for $205M; Hiya had $103M sales, $22M adjusted EBITDA LTM","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 78.8% controlling stake in Hiya Health for $205M cash; closed Dec 23, 2024.","Hiya's LTM (Sept 30, 2024) net sales $103M, net income $19M, adjusted EBITDA $22M.","Hiya serves 200,000+ customers via DTC subscription; net sales grew 50% in 2024 vs 2023.","Transaction expected to be immediately accretive to USANA's 2025 adjusted EBITDA.","Remaining 21.15% rollover equity subject to put/call based on Hiya's future EBITDA; financed from $200M cash on hand and credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201386,"accession_number":"0001628280-24-043281","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q3 net sales $200M (-6% YoY); cuts FY2024 EPS guidance to $2.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 diluted EPS $0.56 vs $0.59 YoY; net sales down 6% to $200M.","Active customers fell 3% YoY to 452,000; Greater China customers rose 6% but sales -4%.","FY2024 outlook narrowed: net sales ~$850M (from $850-880M), EPS $2.45 (from $2.40-2.55).","Balance sheet: $365M cash, debt-free; no shares repurchased in Q3.","Regional weakness: North Asia -15%, Americas & Europe -7% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":1.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":640890000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217405,"accession_number":"0000896264-24-000180","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q2 net sales $213M (-11% YoY), EPS $0.54 (-39%); cuts FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS $0.54 vs. $0.89 in Q2 2023; net sales $213M down 11% YoY to $238M.","Active customers fell 4% YoY to 468,000; macro pressures and fewer promotions cited.","FY24 outlook: net sales $850-880M (prev $850-920M), EPS $2.40-2.55 (prev $2.40-3.00).","Operating margin revised to 8.0%-8.8%; effective tax rate raised to 43%-44%.","Cash $332M, no debt; no share repurchases in Q2; $62M authorization remaining."],"consensus_eps_estimate":null,"consensus_eps_actual":1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":440669000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237251,"accession_number":"0000896264-24-000168","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"USANA shareholders re-elect eight board members, ratify KPMG, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; vote totals ranged from 15.9M (Gilbert Fuller) to 16.86M (Kevin Guest) shares for.","Ratification of KPMG as auditor approved with 17.46M for, 60,804 against, 634 abstain.","Advisory vote on executive compensation approved with 16.56M for, 414,043 against, 3,249 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}